United States Patent 10,959,982 (Duloxetine multiparticulate “sprinkle” with enteric coating and 1-naphthol impurity control): scope, claim map drivers, and US patent landscape
Executive summary: US 10,959,982 claims a specific duloxetine multiparticulate sprinkle architecture (drug-layered inert cores + enteric coating, optional sub-coating and finishing/cushioning layers) with explicit dissolution/impurity acceptance criteria for 1-naphthol impurity in 0.1N HCl using USP apparatus I at 100 rpm. Independent claim 1 is anchored on (i) multiparticulate discrete units, (ii) duloxetine drug layer on inert core, (iii) enteric coating, and (iv) a tight performance gate: release of no more than 15% of 1-naphthol after 6 hours in 1000 mL 0.1N HCl. Dependent claims expand allowable excipient/polymer sets (sub-coating films, enteric polymer list, enteric coating weight fraction, finishing/cushioning agent set and % by weight) and add an additional independent-like performance test in claims 11-12 that changes the exposure and timing criteria and imposes additional duloxetine release limits in early gastric conditions.
What does US Drug Patent 10,959,982 claim cover (scope of the duloxetine sprinkle patent)?
Short answer: The patent protects a duloxetine multiparticulate sprinkle dosage form built from discrete, enteric-coated subunits designed to suppress early gastric release of both (a) duloxetine and (b) the impurity marker “1-naphthol,” measured under specified in vitro dissolution conditions.
Claim 1 (core scope)
Independent claim 1 covers:
- Dosage form type: multiparticulate sprinkle dosage form comprising plurality of discrete units.
- Unit structure: each unit has:
- Core subunit with a drug layered subunit surrounding an inert core, where the drug layer comprises duloxetine or a pharmaceutically acceptable salt.
- Enteric coating layer surrounding the core subunit.
- Performance requirement (impurity): the sprinkle dosage form releases ≤ 15% of 1-naphthol impurity after 6 hours when placed in 1000 mL of 0.1N HCl at 100 rpm in USP apparatus I.
Interpretation for freedom-to-operate: the structural elements (drug-layered inert core + enteric coat) are necessary, and the impurity-release threshold is a quantitative gate that can be used to distinguish competing designs even when enteric coating and multiparticulates are otherwise similar.
Claim 2 (sub-coating film on core)
Claim 2 requires that the core subunit further includes a sub-coating layer formed by a film-forming agent from:
- hydroxypropyl cellulose
- hydroxypropylmethyl cellulose
- ethylcellulose
This is a narrowing “layer-on-layer” restriction.
Claim 3 (enteric coating weight fraction)
Claim 3 narrows to an enteric coating composition range:
- enteric polymer present at about 75% to about 99% by weight of the enteric coating.
This is a formulation-percentage constraint that can be used to avoid literal coverage by changing plasticizers/fillers that reduce polymer fraction.
Claim 4-5 (finishing/cushioning layer over enteric coat)
- Claim 4 adds a finishing layer containing a cushioning agent surrounding the enteric coating.
- Claim 5 requires cushioning agent presence at about 2% to about 20% by weight of the total dosage form.
Claim 6 (duloxetine loading)
Claim 6 narrows drug loading:
- duloxetine (or salt) about 20% by weight of the dosage form.
Claim 7 (enteric polymer species list)
Claim 7 restricts the enteric polymer to one of:
- methacrylic acid copolymers
- cellulose acetate phthalate (CAP)
- cellulose acetate succinate (CAS)
- polymethacrylic acid
- hydroxypropyl methylcellulose phthalate (HPMCP)
- hydroxypropyl methylcellulose (also listed, which overlaps with film former set)
- polyvinyl acetate phthalate (PVAP)
- hydroxyethyl ethyl cellulose phthalate
- cellulose acetate tetrahydrophthalate
- acrylic resin
- mixtures
Claim 7 is a material species list that can function as a “claim scope boundary” against enteric coating systems not falling within the listed polymers.
Claim 8 (cushioning agent species list)
Cushioning agent is limited to:
- polyethylene glycols
- polyoxyethylenes
- colloidal and/or amorphous silicon dioxide
- microcrystalline cellulose
- polyvinyl acetate
- waxes
- fats
- lipids
- gums
- mixtures
Claim 9 (discrete unit physical form)
Discrete units are selected from:
- pellets
- beads
- particles
- granules
- minitablets
This targets the marketed “sprinkle” format rather than bulk tablets.
Claim 10 (alternative impurity gate at earlier time)
Claim 10 requires:
- ≤ 20% of total duloxetine released after 4 hours in the same dissolution condition (1000 mL 0.1N HCl, 100 rpm, USP I).
Claim 10 adds a duloxetine release performance constraint separate from the 1-naphthol impurity limit in claim 1.
How do claims 11-12 expand or change the performance testing (syringe + NG tube scenario)?
Claim 11 adds a use-case and modified dissolution preconditioning:
- Multiparticulate sprinkle dosage form comprising plurality of discrete units comprising duloxetine.
- Pre-test handling: discrete units exposed to water for 60 minutes in a syringe, then passed through a 12 French nasogastric tube into dissolution medium of 0.1N HCl.
- Then measured: releases ≤ 15% of 1-naphthol impurity after 2 hours when placed in 1000 mL 0.1N HCl at 100 rpm in USP apparatus I.
Claim 12 further adds:
- discrete units release ≤ 20% of total duloxetine after 2 hours under the same post-handling dissolution protocol.
Why this matters for scope: claims 11-12 broaden practical relevance to administration after wetting and nasogastric delivery, while keeping the same impurity marker and an earlier timepoint (2 hours instead of 6 hours).
What structural features are required for literal infringement of US 10,959,982?
Based strictly on the claim text, literal infringement analysis for each asserted claim would typically focus on whether all required elements are present:
Non-negotiable elements in claim 1
- Multiparticulate sprinkle dosage form with plurality of discrete units
- Each unit having:
- inert core
- drug-layered subunit around inert core with duloxetine/salt in the drug layer
- enteric coating surrounding core subunit
- Performance threshold: ≤ 15% release of 1-naphthol impurity after 6 hours in 1000 mL 0.1N HCl, 100 rpm, USP apparatus I
Claim 2, 4, 5, 6, 7, 8, 9, 10, 11, 12 add narrowing limitations
- Sub-coating polymer (claim 2)
- Enteric coating polymer weight fraction (claim 3)
- Finishing/cushioning layer and weight %, and cushioning agent species (claims 4-5, 8)
- Duloxetine loading at about 20% (claim 6)
- Enteric polymer selection list (claim 7)
- Discrete unit form (claim 9)
- Specific dissolution timing for duloxetine release (claims 10, 12)
- Specific pre-test syringe + NG tube exposure (claim 11-12)
Which design-arounds are suggested by the claim language (how to reduce literal risk)?
The patent’s limitations point to three primary risk levers: (i) architecture, (ii) material species and proportions, and (iii) in vitro impurity-release performance.
1) Architectural design around: enteric-coated drug-layered pellets vs alternatives
- Claim 1 requires an enteric coating layer around drug-layered inert cores.
- Switching to a different multiparticulate architecture that lacks one of these structural elements could reduce literal coverage.
2) Polymer and composition carve-outs (species and weight % boundaries)
- Enteric polymer species are restricted to a defined list (claim 7). Using an enteric polymer outside the listed species may avoid literal inclusion for claims that require that polymer list.
- Enteric coating polymer fraction is bounded at 75%–99% by weight (claim 3). Using enteric coatings with lower polymer fraction could avoid claim 3 specifically, though it would not necessarily avoid claim 1 unless the competitor also avoids the core claim limitations.
3) Optional layers are potential toggles
- Sub-coating layer is optional in the independent sense (it is required only in claim 2).
- Finishing/cushioning layer is required only in claim 4-5.
4) Performance gate and impurity marker are the tightest boundary
- The most distinctive element is the impurity performance requirement tied to “1-naphthol impurity” released under defined USP dissolution conditions.
- Even if structure is similar, a different impurity control strategy that results in higher or lower 1-naphthol release relative to the thresholds is central to infringement analysis.
How strong is the US patent estate around this invention (what related claims and continuation patterns typically exist)?
Only the claim text provided is available here. A full US landscape assessment (continuations, divisionals, related family members, prosecution history, and other US patents covering adjacent aspects) cannot be produced from the provided information alone without adding additional patent-publication facts. The claim language itself indicates a claim strategy that targets both:
- Formulation architecture (layered cores + enteric coating)
- Quality/safety performance via impurity release thresholds
- Administration practicality via syringe wetting + NG tube passage
That mix is consistent with a patent estate approach where closely related claims cover incremental modifications: different sub-coating agents, enteric polymer options, finishing layers, and altered timepoints.
No additional hard data can be cited on related US-family patents, assignees, or expiry calendars from the inputs provided.
Orange Book status, FDA listings, and generic/biosimilar risk for duloxetine sprinkle products?
The information provided identifies the formulation and the active ingredient (duloxetine), but does not include:
- the specific marketed product name
- NDA/BLA number
- Orange Book patent codes (A/B/C, method-of-use vs formulation, etc.)
- any FDA approval dates or listed patents
A complete Orange Book status and generic-entry risk assessment cannot be produced from the provided claim text alone.
Claim-by-claim scope matrix (what each limitation covers and what it excludes)
| Claim |
Mandatory elements beyond claim 1 |
Key limiting metric(s) |
Scope boundary that supports licensing/ETP |
| 1 |
Baseline multiparticulate sprinkle; inert core with duloxetine drug layer; enteric coating |
≤15% 1-naphthol impurity after 6h in 0.1N HCl (1000 mL), USP I, 100 rpm |
Protects both architecture and impurity release performance |
| 2 |
Core includes sub-coating film from HPC/HPMC/ethylcellulose |
N/A |
Narrows to specific sub-coating agents |
| 3 |
Enteric coating polymer fraction 75%–99% by weight |
N/A |
Narrows formulation composition |
| 4 |
Finishing layer with cushioning agent |
N/A |
Adds optional layer requirement |
| 5 |
Cushioning agent amount 2%–20% by total dosage form weight |
N/A |
Narrows dosage composition |
| 6 |
Duloxetine loading ~20% by weight |
N/A |
Narrows strength/loading |
| 7 |
Enteric polymer must be from listed set |
N/A |
Narrows polymer identity |
| 8 |
Cushioning agent species must be from listed set |
N/A |
Narrows cushioning formulation identity |
| 9 |
Discrete unit type limited to pellets/beads/particles/granules/minitablets |
N/A |
Targets physical format for sprinkle |
| 10 |
Early-time duloxetine release cap |
≤20% total duloxetine after 4h |
Adds duloxetine dissolution performance gate |
| 11 |
Syringe 60 min water exposure then 12F NG tube into dissolution; impurity gate earlier |
≤15% 1-naphthol after 2h |
Protects administration-conditioned behavior |
| 12 |
Adds early-time duloxetine release cap post-handling |
≤20% total duloxetine after 2h |
Tightens combined impurity and API release performance |
Key takeaways
- US 10,959,982 is built around a duloxetine multiparticulate sprinkle design using drug-layered inert cores and an enteric coating, with literal scope tied to quantitative impurity-release control for 1-naphthol in gastric-like conditions.
- The claim’s most distinguishing feature is the dissolution-based impurity metric: ≤15% 1-naphthol after 6 hours (claim 1) and ≤15% 1-naphthol after 2 hours post 60-minute syringe water exposure + 12 French NG tube (claim 11).
- Dependent claims add meaningful narrowing levers: sub-coating polymer identity, enteric polymer species list, enteric polymer weight fraction, finishing/cushioning layer identity and %, duloxetine loading, and early-time duloxetine release caps.
FAQs
- What does “1-naphthol impurity” functionally protect in this patent? It is the quantitative marker used to gate how much impurity is released under defined USP gastric dissolution conditions.
- Do claims require the product to be administered via NG tube? Only claims 11 and 12 require the syringe-water exposure and 12F nasogastric tube passage as part of the test/exposure protocol.
- Can a design avoid infringement by changing enteric polymer plasticizer? Claim 3 uses an enteric polymer weight fraction of 75%–99% for one dependent path; claim 7 restricts enteric polymer to a specified set of polymers.
- Is duloxetine release control tied to the impurity limit? The patent separates the impurity gate (1-naphthol, claim 1/11) from duloxetine release caps at different timepoints (claims 10 and 12).
- What unit formats are covered? The discrete units are explicitly limited to pellets, beads, particles, granules, or minitablets (claim 9).
References
- US Patent 10,959,982 (claim set as provided).
